This knowledge provides a new basis for the development of MET‐targeted therapies, which could interfere with MET signalling pathways and, consequently, with ETS transcription factors, thereby reducing progression to the aggressive stages of prostate cancer. This evidence concerns the gene MET and Familial prostate cancer.